# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN-TD
- Date: 1974-07-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral. **S**

## Objective

Hemoglobin: 15.1 g/dL; Sodium: 139 mmol/L; Potassium: 4 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 1969): 98 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Hemoglobin A1c: 5.8% (high); ALT: 72 U/L (high); AST: 52 U/L (high); GGT: 78 U/L (high); TSH: 2.1 mIU/L; Urine albumin-to-creatinine ratio: 14 mg/g{creat}; PHQ-9: 8; GAD-7: 9; DAST-10: 7; AUDIT-C: 0. All results are synthetic.

BP 154/98 mmHg; pulse 94 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 96% on room air; weight 109 kg; BMI 32.5 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings; Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working; Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation **S**
- Started: Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation **S**
- Started: Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time **S**
- Started: Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time **S**
- Started: Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma **S**
- Started: Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Started: Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Started: Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Started: Senna 8.6 mg oral tablet, two tablets at bedtime **S**

## Plan

- Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptly. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and taper. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
- Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explained. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020) **S**
- Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each review. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomiting. Guideline: American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019); American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023) **S**
- Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with halos. Guideline: Primary Open-Angle Glaucoma Preferred Practice Pattern (2020); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venues. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
